Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia.

Loh KP, Tooze JA, Nicklas BJ, Kritchevsky SB, Williamson JD, Ellis LR, Powell BL, Pardee TS, Goyal NG, Klepin HD.

J Geriatr Oncol. 2019 Apr 5. pii: S1879-4068(19)30041-4. doi: 10.1016/j.jgo.2019.03.014. [Epub ahead of print]

PMID:
30962090
2.

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.

Mrózek K, Eisfeld AK, Kohlschmidt J, Carroll AJ, Walker CJ, Nicolet D, Blachly JS, Bill M, Papaioannou D, Wang ES, Uy GL, Kolitz JE, Powell BL, Blum W, Stone RM, Byrd JC, Bloomfield CD.

Leukemia. 2019 Jul;33(7):1620-1634. doi: 10.1038/s41375-019-0390-3. Epub 2019 Feb 8.

PMID:
30737482
3.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, Jané-Valbuena J, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA.

Blood Adv. 2018 Dec 26;2(24):3608-3617. doi: 10.1182/bloodadvances.2018023689.

4.

Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia.

Kuhlman P, Isom S, Pardee TS, Burns C, Tawfik B, Lamar ZS, Powell BL, Klepin HD.

Support Care Cancer. 2019 Aug;27(8):2877-2884. doi: 10.1007/s00520-018-4582-6. Epub 2018 Dec 15.

PMID:
30554278
5.

Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).

Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH.

Pediatr Blood Cancer. 2019 Mar;66(3):e27542. doi: 10.1002/pbc.27542. Epub 2018 Nov 4.

PMID:
30393935
6.

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.

Walker CJ, Oakes CC, Genutis LK, Giacopelli B, Liyanarachchi S, Nicolet D, Eisfeld AK, Scholz M, Brock P, Kohlschmidt J, Mrózek K, Bill M, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Niederwieser DW, Stone RM, Byrd JC, Schwind S, de la Chapelle A, Bloomfield CD.

Leukemia. 2019 Mar;33(3):771-775. doi: 10.1038/s41375-018-0281-z. Epub 2018 Oct 5. No abstract available.

7.

Surgical Instrument Reprocessing in Resource-Constrained Countries: A Scoping Review of Existing Methods, Policies, and Barriers.

Forrester JA, Powell BL, Forrester JD, Fast C, Weiser TG.

Surg Infect (Larchmt). 2018 Aug/Sep;19(6):593-602. doi: 10.1089/sur.2018.078. Review.

PMID:
30156997
8.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

Vasu S, Kohlschmidt J, Mrózek K, Eisfeld AK, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell BL, Kolitz JE, Moore JO, Baer MR, Roboz GJ, Stone RM, Byrd JC, Carroll AJ, Bloomfield CD.

Blood Adv. 2018 Jul 10;2(13):1645-1650. doi: 10.1182/bloodadvances.2017015222.

9.

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.

Eisfeld AK, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD.

Leukemia. 2018 Dec;32(12):2536-2545. doi: 10.1038/s41375-018-0147-4. Epub 2018 Jun 5.

10.

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.

Eisfeld AK, Kohlschmidt J, Mrózek K, Blachly JS, Walker CJ, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Stone RM, de la Chapelle A, Wang ES, Kolitz JE, Powell BL, Byrd JC, Bloomfield CD.

Leukemia. 2018 Jun;32(6):1338-1348. doi: 10.1038/s41375-018-0068-2. Epub 2018 Feb 25.

11.

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.

Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL.

Clin Cancer Res. 2018 May 1;24(9):2060-2073. doi: 10.1158/1078-0432.CCR-17-2282. Epub 2018 Feb 6.

12.

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.

Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R.

Oncotarget. 2017 Dec 12;9(4):4354-4365. doi: 10.18632/oncotarget.23150. eCollection 2018 Jan 12.

13.

Sepsis + ptosis = an unusual diagnosis.

Powell BL, Morgan OTC.

BMJ Case Rep. 2017 Oct 25;2017. pii: bcr-2017-222023. doi: 10.1136/bcr-2017-222023.

PMID:
29070622
14.

Thyroid hormone fluctuations indicate a thermoregulatory function in both a tropical (Alouatta palliata) and seasonally cold-habitat (Macaca fuscata) primate.

Thompson CL, Powell BL, Williams SH, Hanya G, Glander KE, Vinyard CJ.

Am J Primatol. 2017 Nov;79(11). doi: 10.1002/ajp.22714. Epub 2017 Oct 19.

PMID:
29048740
15.

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA.

Blood Adv. 2017 Jan 24;1(5):331-340. doi: 10.1182/bloodadvances.2016003053.

16.

Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit.

Ahmed T, Koch AL, Isom S, Klepin HD, Bishop JM, Ellis LR, Berenzon D, Howard D, Lyerly S, Powell BL, Pardee TS.

Leuk Res. 2017 Nov;62:51-55. doi: 10.1016/j.leukres.2017.09.017. Epub 2017 Sep 27.

17.

Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.

Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, Wagner LI, Foley KL, Abraham E, Pasche B, Zhang W.

Theranostics. 2017 Jul 12;7(11):2914-2923. doi: 10.7150/thno.20355. eCollection 2017.

18.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

19.

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.

Abla O, Ribeiro RC, Testi AM, Montesinos P, Creutzig U, Sung L, Di Giuseppe G, Stephens D, Feusner JH, Powell BL, Hasle H, Kaspers GJL, Dalla-Pozza L, Lassaletta A, Tallman MS, Locatelli F, Reinhardt D, Lo-Coco F, Hitzler J, Sanz MA.

Ann Hematol. 2017 Sep;96(9):1449-1456. doi: 10.1007/s00277-017-3042-6. Epub 2017 Jun 8.

PMID:
28597167
20.

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.

Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrózek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4641-E4647. doi: 10.1073/pnas.1703142114. Epub 2017 May 22.

21.

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.

Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD.

Haematologica. 2017 Aug;102(8):1391-1400. doi: 10.3324/haematol.2017.166215. Epub 2017 May 4.

22.

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.

Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED, D'Agostino RB Jr, Petro RM, Blackstock W, Powell BL, Abraham E, Pasche B, Zhang W.

J Hematol Oncol. 2017 May 4;10(1):100. doi: 10.1186/s13045-017-0468-1.

23.

No evidence for microsatellite instability in acute myeloid leukemia.

Walker CJ, Eisfeld AK, Genutis LK, Bainazar M, Kohlschmidt J, Mrózek K, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Stone RM, Bundschuh R, de la Chapelle A, Bloomfield CD.

Leukemia. 2017 Jun;31(6):1474-1476. doi: 10.1038/leu.2017.97. Epub 2017 Mar 24. No abstract available.

24.

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.

Eisfeld AK, Mrózek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, Kroll KW, Blachly JS, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD.

Leukemia. 2017 Oct;31(10):2211-2218. doi: 10.1038/leu.2017.86. Epub 2017 Mar 24.

25.

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, Laumann K, Rowe JM, Erba H, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS.

Blood. 2017 Mar 30;129(13):1763-1767. doi: 10.1182/blood-2016-10-747170. Epub 2017 Jan 12.

26.

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.

Eisfeld AK, Kohlschmidt J, Schwind S, Nicolet D, Blachly JS, Orwick S, Shah C, Bainazar M, Kroll KW, Walker CJ, Carroll AJ, Powell BL, Stone RM, Kolitz JE, Baer MR, de la Chapelle A, Mrózek K, Byrd JC, Bloomfield CD.

Leukemia. 2017 Jun;31(6):1278-1285. doi: 10.1038/leu.2016.332. Epub 2016 Nov 15.

27.

Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.

Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, Danhauer SC, Rao AV, Wildes TM, Williamson JD, Powell BL, Kritchevsky SB.

J Am Geriatr Soc. 2016 Oct;64(10):1988-1995. doi: 10.1111/jgs.14301. Epub 2016 Sep 14.

28.

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.

Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP.

Leukemia. 2016 Dec;30(12):2430. doi: 10.1038/leu.2016.237. Epub 2016 Oct 7. No abstract available.

PMID:
27713533
29.

Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.

Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Coutré SE, Lancet J, Litzow MR, Luger SM, Young NS, Tallman MS.

Acta Haematol. 2016;136(4):210-218. Epub 2016 Sep 16.

30.

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).

Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wang ES, Hoke E, Mrózek K, Kohlschmidt J, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology.

Leukemia. 2017 Jan;31(1):34-39. doi: 10.1038/leu.2016.252. Epub 2016 Sep 13.

31.

Vascular ring presenting as dysphagia in an adult woman: a case report.

Powell BL.

Ann R Coll Surg Engl. 2017 Jan;99(1):e3-e5. doi: 10.1308/rcsann.2016.0232. Epub 2016 Aug 23.

32.

Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).

Niederwieser C, Nicolet D, Carroll AJ, Kolitz JE, Powell BL, Kohlschmidt J, Stone RM, Byrd JC, Mrózek K, Bloomfield CD.

Haematologica. 2016 Dec;101(12):1516-1523. Epub 2016 Jul 28.

33.

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.

Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP.

Leukemia. 2016 Aug;30(8):1672-81. doi: 10.1038/leu.2016.69. Epub 2016 Apr 11. Erratum in: Leukemia. 2016 Dec;30(12 ):2430.

34.

Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).

Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, Klepin HD.

J Geriatr Oncol. 2016 Jan;7(1):24-31. doi: 10.1016/j.jgo.2015.10.182. Epub 2015 Oct 30.

35.

Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials.

Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL, Larson RA, Stone RM.

Am J Hematol. 2016 Feb;91(2):199-204. doi: 10.1002/ajh.24230. Epub 2015 Nov 26.

36.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.

Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.

37.

High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.

Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS.

Leuk Res. 2015 Sep;39(9):945-9. doi: 10.1016/j.leukres.2015.05.010. Epub 2015 Jun 1.

38.

Donor-derived myeloid sarcoma in two kidney transplant recipients from a single donor.

Palanisamy A, Persad P, Koty PP, Douglas LL, Stratta RJ, Rogers J, Reeves-Daniel AM, Orlando G, Farney AC, Beaty MW, Pettenati MJ, Iskandar SS, Grier DD, Kaczmorski SA, Doares WH, Gautreaux MD, Freedman BI, Powell BL.

Case Rep Nephrol. 2015;2015:821346. doi: 10.1155/2015/821346. Epub 2015 Apr 21.

39.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL.

Blood. 2015 Feb 26;125(9):1367-76. doi: 10.1182/blood-2014-11-610543. Epub 2014 Dec 30.

40.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18679-84. doi: 10.1073/pnas.1422050112. Epub 2014 Dec 15.

41.

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.

Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K, Marcucci G, Bloomfield CD.

Leukemia. 2015 Mar;29(3):567-75. doi: 10.1038/leu.2014.267. Epub 2014 Sep 10.

42.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.

Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.

Clin Cancer Res. 2014 Oct 15;20(20):5255-64. doi: 10.1158/1078-0432.CCR-14-1019. Epub 2014 Aug 27.

43.

The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).

Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD.

Leuk Res. 2014 Oct;38(10):1184-90. doi: 10.1016/j.leukres.2014.06.018. Epub 2014 Jul 7.

44.

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.

Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CD.

Leukemia. 2014 Aug;28(8):1754-1758. doi: 10.1038/leu.2014.114. Epub 2014 Mar 21. No abstract available.

45.

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA; Alliance for Clinical Trials In Oncology (ACTION).

Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15.

46.

Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.

Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA; Alliance for Clinical Trials in Oncology.

Cancer. 2014 Apr 1;120(7):1010-7. doi: 10.1002/cncr.28516. Epub 2013 Dec 31.

47.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield CD.

J Clin Oncol. 2014 Feb 20;32(6):548-56. doi: 10.1200/JCO.2013.50.6337. Epub 2013 Dec 30.

48.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.

Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD.

Leukemia. 2014 Jun;28(6):1252-1258. doi: 10.1038/leu.2013.371. Epub 2013 Dec 11.

49.

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.

Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W.

Leuk Lymphoma. 2014 Jul;55(7):1523-32. doi: 10.3109/10428194.2013.842985. Epub 2014 Feb 4.

50.

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).

Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T.

Ann Hematol. 2014 Jan;93(1):47-55. doi: 10.1007/s00277-013-1940-9. Epub 2013 Oct 23.

Supplemental Content

Loading ...
Support Center